MA55885A - Chélateurs macrocycliques et leurs procédés d'utilisation - Google Patents
Chélateurs macrocycliques et leurs procédés d'utilisationInfo
- Publication number
- MA55885A MA55885A MA055885A MA55885A MA55885A MA 55885 A MA55885 A MA 55885A MA 055885 A MA055885 A MA 055885A MA 55885 A MA55885 A MA 55885A MA 55885 A MA55885 A MA 55885A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- macrocyclic chelators
- macrocyclic
- chelators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962846044P | 2019-05-10 | 2019-05-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55885A true MA55885A (fr) | 2022-03-16 |
Family
ID=70804855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055885A MA55885A (fr) | 2019-05-10 | 2020-05-08 | Chélateurs macrocycliques et leurs procédés d'utilisation |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11576986B2 (fr) |
| EP (1) | EP3966211A1 (fr) |
| JP (1) | JP2022532157A (fr) |
| KR (1) | KR20220006613A (fr) |
| CN (1) | CN114127059A (fr) |
| AU (1) | AU2020273654A1 (fr) |
| BR (1) | BR112021022237A2 (fr) |
| CA (1) | CA3139806A1 (fr) |
| CL (1) | CL2021002960A1 (fr) |
| CO (1) | CO2021015713A2 (fr) |
| CR (1) | CR20210556A (fr) |
| DO (1) | DOP2021000233A (fr) |
| EA (1) | EA202193076A1 (fr) |
| EC (1) | ECSP21089217A (fr) |
| IL (1) | IL287909A (fr) |
| MA (1) | MA55885A (fr) |
| MX (1) | MX2021013667A (fr) |
| PE (1) | PE20220935A1 (fr) |
| SG (1) | SG11202112100PA (fr) |
| WO (1) | WO2020229974A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021250240A1 (fr) * | 2020-06-12 | 2021-12-16 | Orano | Dérivé de diaza-18-crown-6 utile pour chélater le radium, conjugué et chélate de radium comprenant ce dérivé et utilisations correspondantes |
| KR20230106666A (ko) * | 2020-11-10 | 2023-07-13 | 얀센 바이오테크 인코포레이티드 | 마크로사이클릭 화합물 및 이의 사용 방법 |
| WO2022162549A2 (fr) | 2021-01-27 | 2022-08-04 | Janssen Biotech, Inc. | Immunoconjugués comprenant des domaines de liaison à l'antigène de peptidase 2 liée à la kallicréine et leurs utilisations |
| WO2022203082A1 (fr) * | 2021-03-26 | 2022-09-29 | 日本メジフィジックス株式会社 | Composé, procédé de production et procédé de stockage d'un composé, procédé de production d'un agent de ciblage et composition |
| US20240207463A1 (en) * | 2021-03-31 | 2024-06-27 | Nihon Medi-Physics Co., Ltd. | Radioactive complex of anti-egfr antibody, and radiopharmaceutical |
| IL308766A (en) | 2021-05-27 | 2024-01-01 | Janssen Biotech Inc | Compositions and methods for treating prostate cancer |
| KR20240053674A (ko) * | 2021-08-02 | 2024-04-24 | 레이즈바이오, 인크. | 방사성 핵종의 안정화된 조성물 및 이의 용도 |
| WO2023013589A1 (fr) * | 2021-08-03 | 2023-02-09 | 住友化学株式会社 | Complexe métallique radioactif et procédé pour le produire, et piégeur de métaux radioactifs |
| AU2022333321A1 (en) | 2021-08-27 | 2024-04-11 | Janssen Biotech, Inc. | Anti-psma antibodies and uses thereof |
| CA3230156A1 (fr) * | 2021-08-27 | 2023-03-02 | Janssen Biotech, Inc. | Radioconjugues anti-psma et leurs utilisations |
| WO2023049963A1 (fr) * | 2021-09-29 | 2023-04-06 | The University Of Melbourne | Composés contenant un macrocycle et leurs complexes radiomarqués, utilisés en tant que ligands dans des applications de radiothérapie ciblée |
| WO2023084397A1 (fr) * | 2021-11-09 | 2023-05-19 | Janssen Biotech, Inc. | Composés macrocycliques et leurs utilisations diagnostiques |
| CA3240194A1 (fr) * | 2021-11-09 | 2023-05-19 | Edward Cleator | Composes macrocycliques et leurs procedes de fabrication |
| WO2023144723A1 (fr) | 2022-01-26 | 2023-08-03 | Janssen Biotech, Inc. | Immunoconjugués comprenant des domaines de liaison à l'antigène de peptidase 2 associés à la kallicréine et leurs utilisations |
| CN114656422B (zh) * | 2022-04-22 | 2023-05-23 | 重庆理工大学 | 一种新型氮杂冠醚化合物及其阳离子脂质体、制备方法与应用 |
| CN114874214B (zh) * | 2022-05-31 | 2023-03-21 | 南京航空航天大学 | 可偶联巯基的双功能大环螯合剂衍生物及其制备方法 |
| CN114949259B (zh) * | 2022-07-11 | 2023-09-19 | 重庆理工大学 | 一种氮杂冠醚结构的基因递送载体及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE353450T1 (de) * | 1988-06-24 | 1990-09-06 | The Dow Chemical Co., Midland, Mich. | Macrocyclische bifunktionelle chelatbildner, komplexe davon und ihre konjugierten antikoerper. |
| WO2012012612A2 (fr) | 2010-07-23 | 2012-01-26 | University Of Delaware | Ligature tétrazine-trans-cyclooctène pour la construction rapide de sondes marquées par un radionucléide |
| US10556024B2 (en) | 2013-11-13 | 2020-02-11 | Whitehead Institute For Biomedical Research | 18F labeling of proteins using sortases |
| CA2930493A1 (fr) | 2013-11-19 | 2015-05-28 | Fredax Ab | Anticorps anti-kallikreine-2 humanise |
| CA3058454A1 (fr) * | 2017-03-30 | 2018-10-04 | Cornell University | Complexes macrocycliques de radionucleides emetteurs alpha et leur utilisation en radiotherapie ciblee contre le cancer |
| CA3058663A1 (fr) | 2017-04-05 | 2018-10-11 | Cornell University | Constructions trifonctionnelles avec pharmacocinetiques reglables utiles dans les therapies d'imagerie et antitumorales |
| WO2019090242A1 (fr) * | 2017-11-04 | 2019-05-09 | Advanced Proteome Therapeutics Inc. | Composition et procédé pour modifier des polypeptides |
| CN111491670A (zh) | 2017-12-18 | 2020-08-04 | 詹森生物科技公司 | 多肽的放射性标记 |
| SG11202011633SA (en) | 2018-05-24 | 2020-12-30 | Janssen Biotech Inc | Psma binding agents and uses thereof |
| US11279698B2 (en) * | 2018-11-20 | 2022-03-22 | Cornell University | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer |
-
2020
- 2020-05-08 US US16/869,771 patent/US11576986B2/en active Active
- 2020-05-08 KR KR1020217040423A patent/KR20220006613A/ko unknown
- 2020-05-08 SG SG11202112100PA patent/SG11202112100PA/en unknown
- 2020-05-08 PE PE2021001868A patent/PE20220935A1/es unknown
- 2020-05-08 MA MA055885A patent/MA55885A/fr unknown
- 2020-05-08 BR BR112021022237A patent/BR112021022237A2/pt unknown
- 2020-05-08 MX MX2021013667A patent/MX2021013667A/es unknown
- 2020-05-08 EA EA202193076A patent/EA202193076A1/ru unknown
- 2020-05-08 EP EP20727846.6A patent/EP3966211A1/fr active Pending
- 2020-05-08 CN CN202080050202.0A patent/CN114127059A/zh active Pending
- 2020-05-08 WO PCT/IB2020/054381 patent/WO2020229974A1/fr active Application Filing
- 2020-05-08 CA CA3139806A patent/CA3139806A1/fr active Pending
- 2020-05-08 AU AU2020273654A patent/AU2020273654A1/en active Pending
- 2020-05-08 JP JP2021566438A patent/JP2022532157A/ja active Pending
- 2020-05-08 CR CR20210556A patent/CR20210556A/es unknown
-
2021
- 2021-11-08 IL IL287909A patent/IL287909A/en unknown
- 2021-11-09 CL CL2021002960A patent/CL2021002960A1/es unknown
- 2021-11-10 DO DO2021000233A patent/DOP2021000233A/es unknown
- 2021-11-23 CO CONC2021/0015713A patent/CO2021015713A2/es unknown
- 2021-12-09 EC ECSENADI202189217A patent/ECSP21089217A/es unknown
-
2022
- 2022-06-30 US US17/810,316 patent/US20230110178A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL287909A (en) | 2022-01-01 |
| US20230110178A1 (en) | 2023-04-13 |
| US11576986B2 (en) | 2023-02-14 |
| ECSP21089217A (es) | 2022-01-31 |
| BR112021022237A2 (pt) | 2022-03-29 |
| CO2021015713A2 (es) | 2021-11-30 |
| MX2021013667A (es) | 2022-01-31 |
| CN114127059A (zh) | 2022-03-01 |
| JP2022532157A (ja) | 2022-07-13 |
| CA3139806A1 (fr) | 2020-11-19 |
| US20200353105A1 (en) | 2020-11-12 |
| PE20220935A1 (es) | 2022-05-31 |
| SG11202112100PA (en) | 2021-11-29 |
| DOP2021000233A (es) | 2022-07-31 |
| EP3966211A1 (fr) | 2022-03-16 |
| CL2021002960A1 (es) | 2022-06-24 |
| CR20210556A (es) | 2021-12-17 |
| KR20220006613A (ko) | 2022-01-17 |
| EA202193076A1 (ru) | 2022-02-16 |
| WO2020229974A1 (fr) | 2020-11-19 |
| AU2020273654A1 (en) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55885A (fr) | Chélateurs macrocycliques et leurs procédés d'utilisation | |
| MA55136A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52753A (fr) | Anticorps anti-sirpa et leurs procédés d'utilisation | |
| MA55890A (fr) | Modulateurs de thr-beta et leurs procédés d'utilisation | |
| MA54538A (fr) | Inhibiteurs d'apol1 et leurs procédés d'utilisation | |
| MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
| MA51848A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52501A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52765A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52496A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA51837A (fr) | Inhibiteurs de l'arginase et leurs procédés d'utilisation | |
| MA54594A (fr) | Stéroïdes neuroactifs et leurs procédés d'utilisation | |
| MA47499A (fr) | Anticorps anti-tau et leurs procédés d'utilisation | |
| MA50077A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA48772A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA54261A (fr) | Inhibiteurs de pcsk9 et leurs procédés d'utilisation | |
| MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
| MA44740A (fr) | Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation | |
| MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
| MA44490A (fr) | Adhésifs biocompatibles et leurs procédés d'utilisation | |
| MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA53919A (fr) | Constructions d'acides nucléiques et procédés d'utilisation |